Incyte (INCY)
(Delayed Data from NSDQ)
$68.06 USD
+1.96 (2.97%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $67.78 -0.28 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.06 USD
+1.96 (2.97%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $67.78 -0.28 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Incyte Treats First Patient in Phase II GVHD Study on Jakafi
by Zacks Equity Research
Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.
Two Key FDA Decisions to Watch Out for in January 2017
by Arpita Dutt
Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
Incyte/Merus Ink Collaboration for Bispecific Antibodies
by Zacks Equity Research
Incyte (INCY) entered into an agreement with Merus (MRUS) to discover and develop bispecific antibodies using the latter's proprietary Biclonics technology platform.
Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis
by Zacks Equity Research
Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
by Zacks Equity Research
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
by Zacks Equity Research
Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
New Strong Buy Stocks for October 11th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
New Strong Buy Stocks for August 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include OPHT, XNPT, OSUR, INCY and AGIO.